2012
DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.
Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer M, Guarducci C, Symmans W, Hortobagyi G, Pusztai L, Giampaolo B. DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. Journal Of Clinical Oncology 2012, 30: 1012-1012. DOI: 10.1200/jco.2012.30.15_suppl.1012.Peer-Reviewed Original ResearchPathological complete responseHigher pathological complete responseBreast cancer molecular subtypesTaxane-based regimensTaxane-containing regimensCisplatin-containing regimensMolecular breast cancer subtypesTaxane-based chemotherapyPotential predictive markerBreast cancer subtypesCancer molecular subtypesBC cell linesFalse discovery correctionDistant relapseComplete responseBetter prognosisPoor prognosisPredictive factorsPrognostic valueBC subtypesER-/HER2Predictive markerN patientsPrognostic markerMolecular subtypes
2007
Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes
Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. Journal Of Clinical Oncology 2007, 25: 586-586. DOI: 10.1200/jco.2007.25.18_suppl.586.Peer-Reviewed Original ResearchClinical responseTaxane sensitivityPreoperative therapyPrognostic factorsHER2 tumorsProspective studyBreast cancerDocetaxel/capecitabineDocetaxel/doxorubicinTaxane-containing regimensLarge prospective studiesPrimary breast cancerClinical prognostic factorsHER2- breast cancerNovel predictive markerCyclin-dependent kinase 1Breast tumor responseLogistic regression modelsEvaluable ptsAdjuvant therapyClinical outcomesPreclinical findingsPredictive markerTumor responseHER2 overexpressionIdentification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients
Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, Symmans W, Zerba K, Pusztai L, Clark E. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. Journal Of Clinical Oncology 2007, 25: 2525-2525. DOI: 10.1200/jco.2007.25.18_suppl.2525.Peer-Reviewed Original ResearchBreast cancer patientsER patientsCancer patientsPredictive markerClinical trialsPaclitaxel activityER-negative breast cancer patientsComplete pathological responseER-negative patientsTaxane-containing regimensTaxane-containing therapyExpression levelsIxabepilone treatmentPatient selectionBC patientsPathological responseIxabepilonePatientsTherapeutic valueProtein 3SiRNA studiesDifferential markersROC curveTrialsCandidate markers